Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
or alternatively email medinfo.uk@novartis.com or call 01276 698370
This meeting is organised and funded by Novartis Pharmaceuticals UK Ltd and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code. It is intended for UK healthcare professionals only.
Company products will be discussed at this meeting and United Kingdom prescribing information is available by clicking on the purple button above.
This website is created and funded by Novartis.
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 who are candidates for systemic therapy; active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hidradenitis suppurativa therapy
UK | February 2025 | FA-11360274
Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.
The chat tool to the right is managed by Square Production Ltd on behalf of Novartis.